At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 299 enrolled
Drug / intervention
Ga-68 labeled PSMA-11 PETdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
In Brief
A Phase 3 clinical trial evaluating Ga-68 labeled PSMA-11 PET for Prostate Cancer. Completed, enrolled 299 participants across 1 site.
Detailed Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedSep 2016
Primary CompletionDec 2019
TodayJul 2026
First PostedSep 29, 2016
Enrollment StartSep 23, 2016
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.8 years ago
Interventions
Ga-68 labeled PSMA-11 PETdrug
Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.